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DObjective: Transcatheter replacement or repair of mitral valve regurgitation has proved demanding. We aimed
for a new approach to anchor a biologic heart valve in the mitral position by inserting a valve-carrying hollow
body into the left atrium. This approach was investigated in both a simulation and an animal model.
Methods: After creating a mold representing the porcine left atrium from the pulmonary veins as far as the mitral
valve, a nitinol skeleton was sutured onto interlaced yarns of polyvinylidene flouride fitting the mold. The result-
ing device was equipped with a commercially available stentless valve (25 mm) and investigated in a simulator
regarding basic functionality. Furthermore, the device was implanted in 8 female pigs through incision of the left
atrium during extracorporeal circulation. Before implantation, artificial regurgitation was created by means of ex-
cision from the posterior mitral leaflet. Hemodynamic, echocardiographic, and radiologic examinations followed.
For a postmortem examination, the entire heart and the lungs were excised.
Results: We could demonstrate the functionality of the heart valve in a complex, collapsible, and self-expanding
hollow body. The device adapted to the surrounding structures, leading to an exclusion of the left atrium. Suffi-
cient treatment of mitral regurgitation was monitored hemodynamically and by means of echocardiographic anal-
ysis, although overall visualization remained difficult. Therefore in 4 animals computed tomographic scans were
performed. Autopsy revealed proper positioning without major trauma to the surrounding structures.
Conclusion: Anchoring an additional heart valve in the atrioventricular position does not necessarily need to be
performed in the heart valve structure itself. Placement of an additional valve in the mitral position is feasible
through this approach. (J Thorac Cardiovasc Surg 2010;140:97-102)Following basic research in the field of interventional valve
therapies,1-4 transcatheter implantation of an aortic valve
prosthesis has lately become an established method with
commercially available prostheses.5-7 Also, pulmonary
valve placement has been realized.8
In western countries mitral regurgitation is one of the most
frequent atrioventricular (AV) valve diseases. For many rea-
sons, the state of the art is reconstruction of an AV valve
rather than replacement. One important aspect is preserva-
tion of the subvalvular structures, which are essential for
ventricular performance. Because interventional mitral
valve therapies9-11 do not exhibit the same striking results
as interventional aortic or pulmonary valve placements, mi-
tral and tricuspid valve therapy mainly remains a task of car-
diac surgery.12 Interventional placement of a biologic valve
in the AV valve position has been marginally investigated.e Clinics for Cardiothoracic and Vascular Surgery,a Diagnostic Radiology,d
naesthesiology,e University Hospital RWTH Aachen; the Institute for Textile
nology (ITA),b RWTH University Aachen; and Applied Medical Engineering,c
holtz Institute Aachen, Aachen, Germany.
ures: This study has been supported by the HOLSTE–Stiftung, Aachen,
any.
d for publication July 7, 2009; revisions received Aug 18, 2009; accepted for
cation Sept 17, 2009; available ahead of print Nov 12, 2009.
for reprints: Andreas Goetzenich, MD, Department of Anesthesiology, Uni-
y Hospital RWTH Aachen, Pauwelsstr. 30, D-52074 Aachen, Germany.
23/$36.00
ht  2010 by American Association for Thoracic Surgery
016/j.jtcvs.2009.09.037
The Journal of Thoracic and CThis is due to the challenging anatomy the mitral valve pres-
ents: its annulus and D-shaped circumference lack a suffi-
cient abutment for an annulus-matched anchoring that
avoids interference with native valve function or the ventric-
ular outflow tract. In contrast to the emerging technologies
for interventional mitral valve repair, our concept was to
deliver a self-expanding hollow body carrying a stentless
valve prosthesis that would be suspended in the atrium.
The mitral valve was chosen to prove our new concept for
AV valve therapy, which should be easily adaptable to the
tricuspid valve.
Our goal for interventional AV valve therapy was to eval-
uate the placement of a prosthetic heart valve without the
necessity to use the annulus and valve itself for fixation.
We aimed to build a prosthesis coating the entire atrial
wall from the mitral annulus into the pulmonary veins.
This approach would allow the positioning of an additional
prosthetic valve in the mitral position, preventing damage to
the native valve, the annulus, and the subvalvular apparatus.
An additional valve has the theoretic advantage that
interventions on the native valve are not necessary, saving
the remaining function of the valve. The integrity of the
valve–ventricular complex is saved. Furthermore, the addi-
tional placement of a valve is probably easier to manage
from the hemodynamic point of view than a real replacement
because this would imply a time without any functioning AV
barrier in a beating heart. An additional effect on leakardiovascular Surgery c Volume 140, Number 1 97
Abbreviations and Acronyms
AV ¼ atrioventricular
CPB ¼ cardiopulmonary bypass
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Dtightness was expected because of pressure on the annulus
and exclusion of the entire left atrium.
To evaluate this approach, we designed several prosthetic
prototypes, tested their functionality in vitro, and investi-
gated their performance in a porcine model of mitral insuffi-
ciency.MATERIALS AND METHODS
Prosthesis and In Vitro Testing
The intended prosthesis should cover the entire atrial wall from the pul-
monary veins down to the mitral annulus and contain a biologic heart valve
(Figure 1, A). We aimed to realize the following requirements: a compress-
ible device with strong self-expansion after release, stability toward com-
pression vertical to the valve plain, shape memory, and low
thrombogenicity on the inner surface. In preliminary studies we compared
single-wall designs, profiting from a strong self-expanding metallic skeleton
to double-walled inflatable models. Although double-walled designs
showed smaller sizes in the compressed state, we favored a single-wall de-
sign because of the higher stability. The prosthesis hollow body was built of
polyvinylidene fluoride with an external nitinol skeleton for stability. Two
extensions fit into the pulmonary vein ostia. Molds of the porcine atria al-
lowed adaption to the porcine anatomy. The resulting prototype comprised
a stentless valve (SJM Toronto SPV, 25 mm; St Jude Medical, Inc, St Paul,
Minn) and nitinol brackets joining the prosthesis’ rim to the pulmonary vein
stents (Figure 1, B). The load from the valve was displaced through the ni-
tinol skeleton to the atrial wall and the pulmonary vein ostia. Eight such
prostheses were manufactured in cooperation with the Institute for Textile
Technology.
All prostheses were first observed and tested in the pulsatile circulatory
mock-loop simulator at the Aachen Helmholtz Institute. For this cause, an
elastic silicone model of the porcine left atrium, including the pulmonary
veins and the upper part of the mitral valve, was generated. Observation
of the prostheses’ behavior and valve function inside the model atrium
was facilitated by the model’s opacity. The prostheses were compressed, in-
serted through the mitral valve part of the model atrium, and released again.
Thereafter, the model was connected to the simulator with an inlet through
the pulmonary veins and outflow through the mitral valve. Pulsatile circula-
tion was established and continued for 180 minutes. The circulatory mock-
loop simulator worked at heart rates of 70 up to 110 beats/min and at cardiac
outputs of 2, 4, 5, and 7 L/min, respectively (US Food and Drug Adminis-
tration requirements). It was filled with saline. Positioning of the hollow
body, its stability, and the function of the embedded valve prosthesis
were monitored.
Animal Model
Eight female pigs of 70 kg body weight were used for the animal inves-
tigations. The animal research protocol was approved by the local authori-
ties (9.93.2.10.35.07.013). The experimental animals received humane care
in accordance with the applicable National Institutes of Health publication
(no. 86-23, revised 1985). Routine monitoring and catheterization for car-
diothoracic surgery was performed. All animals were killed humanely after
completion of the investigation. After premedication, general anesthesia
was induced, followed by baseline measurement of hemodynamics. Double
peripheral venous cannulation (25F, Biomedicus; Medtronic, Minneapolis,98 The Journal of Thoracic and Cardiovascular SurgeMinn) was performed, followed by a left thoracotomy in the sixth intracostal
space. An arterial cannula (22F, DLP) was inserted and fixed to the descend-
ing aorta. The pericardium was opened, and the left atrium was exposed. Af-
ter therapeutic heparinization, normothermic full cardiopulmonary bypass
(CPB) was established. The following procedures were performed on the
beating heart. The left atrium was longitudinally incised for about 5 cm.
The native mitral valve was then inspected, and an artificial insufficiency
was created by a 0.5 cm2 excision from the posterior valve leaflet. The
size of the left atrium was compared with that of the manufactured prosthe-
ses, and the right size was chosen by means of visual inspection.
The crimped prosthesis was inserted through the atrial incision. First, the
pulmonary vein stents were placed into the ostia, and the stents were ex-
panded. Then the remaining prosthesis with the valve was placed above
the mitral annulus, and the hollow body was released. After deairing, the
left atrium was closed with sutures. The animal was slowly weaned from
CPB and decannulated. Coagulation was reconstituted with protamine to
an activated clotting time of less than 120 seconds.
Repeated epicardial, transthoracic, and transesophageal echocardio-
graphic analysis (GE Vivid 5; GE Healthcare, Waukesha, Wis) was per-
formed, as well as postinterventional hemodynamic measurements
(Datex-Ohmeda, GE Healthcare) and radiologic investigations (fluoroscopy
and computed tomography; Siemens, Berlin, Germany).
The animals were killed after 90 minutes of postoperative observa-
tion and investigation and 60 minutes after administration of prot-
amine. For postmortem examination, the heart was carefully excised
with adjacent lungs. Both the lung veins and the left ventricle were
opened before the left atrium to completely check positioning. After
careful washing with saline, the prostheses were studied to identify
clot formation.RESULTS
Prosthesis In Vitro Testing
Before implantation, all prostheses were investigated in
the circulatory simulator. The construction method of the
simulator together with the transparent model atrium al-
lowed a good assessment of the prosthesis’ overall perfor-
mance (Figure 2). Also, the implantation procedure of the
prosthesis could be controlled by means of visual inspection.
A simple technique was developed to compress and release
the 2 extensions and the main body independently. For im-
plantation, the completely compressed prosthesis had a di-
mension of about 1.5 3 9.5 cm. After insertion of the
prosthesis into the atrium, the 2 venous extensions were re-
leased one after the other, followed by the release of the main
body. All prostheses fitted the model atria very well. There
were no dislodgements of the expanded prosthesis, even at
a maximal circulation of 7 L/min. The prosthesis laid tightly
on the model annulus in all cases. The valve re-expanded in-
side the prosthesis, and there was no visual evidence for ste-
nosis or insufficiency. In one case the suture fixation
between the prosthesis body and the prosthetic valve became
insufficient over time. This problem was solved by resutur-
ing.Animal Experiments
All 8 animals survived the operation, CPB time, and the
follow-up of 90 minutes without CPB. The prostheses could
be surgically implanted through the longitudinal atriotomyry c July 2010
FIGURE 2. Prosthesis prototype in a circulatory mock-loop simulator.
FIGURE 1. Schematic drawing of a prosthesis (blue) in the left porcine
atrium with 2 pulmonary veins (A) and an early prototype of the prosthesis
with an integrated valve (B). AV, Aortic valve; LVOT, left ventricular out-
flow tract; LV, left ventricle; MV, mitral valve.
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sometimes challenging. In one case atrial fibrillation oc-
curred during implantation and was successfully treated
with electrolytes and a single shot of 300 mg of amiodarone.
After termination of CPB and a brief compensatory period,
hemodynamics reached a steady state comparable with pre-
procedural conditions in all animals. In particular, there was
no evidence for a significant pulmonary hypertension or a V
wave in the wedge pressure recording.
Echocardiography turned out to be very difficult, probably
because of the amount of foreign material inside the heart.
Although many acoustic windows were tried in each animal,
only limited echocardiographic access to the valve prosthe-
sis was possible. The prosthesis showed good adaptation
in the region of the mitral annulus, and no relevant move-
ment of the prosthesis was detectable. Both the native and
the prosthetic mitral valve moved synchronously (Figure 3).
There was no evidence for left ventricular outflow tract
obstruction or deformation of the aortic root in any case. Al-
though a higher-grade mitral regurgitation was seen at theThe Journal of Thoracic and Cposterior leaflet of the native valve (artificial defect), the in-
sufficiency jet was stopped at the additional valve. The valve
prosthesis itself appeared with a normal movement of the
cusps and without regurgitation or stenosis. Echocardio-
graphically, it was not possible to gain information about
paravalvular leakage or adherence to the atrial wall.
Fluoroscopic analysis was performed both as angio-
graphic analysis through the pulmonary artery and ventricu-
lographic analysis from the apex of the left ventricle. These
radiographic investigations demonstrated full patency of
the pulmonary veins into the atrium and straight passage of
the contrast medium into the ventricle. No relevant regurgi-
tation over the prosthetic valve could be detected. A slight de-
posit of contrast medium was seen in the area of the anterior
mitral leaflet between the atrial wall and the prosthesis. After
restoration of coagulation capacity, no relevant hemody-
namic changes indicating severe clot formation or valve
thrombosis occurred.
As a result of difficult visualization, the last 4 animals
were subjected to a computed tomographic scan. In this in-
vestigation the intended proper position of the prosthesis in
the left atrium could be verified (Figure 4). Nevertheless, ac-
curate information about paraprosthetic leakage was still not
possible.
Autopsy revealed a correct (intended) overall position of
the prosthesis in all cases. The prosthesis body was pressed
onto the mitral valve annulus, and in 3 animals a slight glid-
ing of the prosthesis into the mitral valve was seen. Except
for one case of a dislodged skeletal strut, there was no trauma
to intracardiac structures. No relevant restriction of the
mitral valve leaflets and no left ventricular outflow tract
obstruction could be detected (Figure 5, A). In one case im-
proper release of the prosthesis extension led to an occlusion
of the right pulmonary vein. In another case a small tear in
the right pulmonary vein caused by a sharp dislodged strut
had to be recognized. In all other animals, the extensions
of the prosthesis could be found in a proper position in the
pulmonary vein ostia, sufficiently draining the pulmonary
veins (Figure 5, B). No relevant thrombus was found inside
the entire prosthesis.ardiovascular Surgery c Volume 140, Number 1 99
FIGURE 3. Epicardial echocardiographic image of the mitral valve with an additional prosthesis (red) in the closed (A) and opened (B) state. LV, Left
ventricle; LA, left atrium.




Surgical repair is by far the most successful treatment
for mitral valve disease. Nevertheless, in the last decade, in-
terventional treatment of valve diseases emerged for high-
risk patients, with strikingly good results, especially in the
treatment of aortic stenosis. For AV valves, especially for
the mitral valve, several interventional approaches to treat
insufficiencies were proposed,9 and some of them are still
on the bench. In contrast to the results in interventional aortic
valve treatment, clinical results for the repair of AV valves
have not been that striking. Mainly, second-choice surgical
techniques are translated into interventional techniques,
such as the Alfieri stitch being translated into the Evalve Mi-
traClip with thus far limited success. Yet all these techniques
are still being improved, and further approaches to beating-
heart valve therapy are investigated.13,14
The interventional placement of a prosthetic valve in the
AV position is rarely investigated because the issue of an-
choring is very challenging.15 The AV valve structure is
not tubular and, therefore, a simple stent cannot be placed.
Furthermore, the valve and its annulus are an integrated
part of contraction and ventricular function. Movement of
the leaflets also provides sustained forward flow of the
blood.FIGURE 4. Computed tomogram showing a prosthesis in the va
100 The Journal of Thoracic and Cardiovascular SurgOur concept allowed us to show that it is indeed possible
to place an additional valve without compromising the
native valvular function of both the aortic and mitral valves.
The angled AV passage makes it very demanding to find the
right site for anchoring a foreign body without danger to the
surrounding structures. It is particularly significant to avoid
outflow tract obstruction that could occur in the case of an
intravalvular placement of a prosthetic valve. Our approach
was to spread the force transduction as evenly as possible
over the entire atrial wall up to the pulmonary vein ostia to
avoid protrusion and the resulting compression to surround-
ing structures. We did not monitor any harm to the outflow
tract or aortic valve function and demonstrated normal
movement of the remaining mitral cusps.
The principle to exclude a pathology from blood flow was
one of the first purposes of interventional therapies. Inter-
ventional exclusion of aortic aneurysms has shown excellent
results. Nevertheless, apart from the exclusion of the left
atrial appendage to prevent strokes,16 no further exclusions
of parts of the heart had been investigated thus far. In our in-
vestigation an exclusion of the whole left atrium was in-
tended as a part of valve fixation. We demonstrated that
insertion of a through-flown hollow body to exclude a heart
chamber is feasible and does not lead to hemodynamiclve plane (A) and in a slightly oblique longitudinal axis (B).
ery c July 2010
FIGURE 5. Autopsy specimen with a view from the apex showing the prosthetic mitral valve and unobstructed outflow tract (A) and drainage of both
pulmonary veins (B).
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the prosthesis body from the atrial wall in the area of the
anterior mitral leaflet, there was no continuous extra-pros-
thetic blood flow reaching the pulmonary veins. It is as-
sumed that in the long run these wake zones will clot and
provide additional tightness. The lost atrial contraction
seems not to be relevant in AV valve diseases because atrial
contraction is already compromised in many cases as a result
of atrial fibrillation and dilatation. In contrast, the relevance
of a large foreign surface inside the hollow body regarding
thrombosis cannot be judged by our investigations because
long-term experiments would be needed. Chronic anticoa-
gulation will surely be needed.Complexity of Transfer to Interventional Application
in Patients
Our work investigated the principal feasibility of anchor-
ing a biologic heart valve in the AV position by inserting
a valve-carrying hollow body into the atrium. The prelimi-
nary design of our prosthesis led to minor technical prob-
lems, such as the slight dehiscence of the prosthesis in the
area of the anterior mitral leaflet or fracture of the nitinol
struts. A more professional design should be able to over-
come these flaws. Although we constructed a collapsible
self-expanding prosthesis, we chose an open surgical access
with CPB for insertion. A minimally invasive or transcath-
eter placement was put on hold because the major principal
questions of such an approach had to be cleared. In its cur-
rent form, a transapical implantation seems favorable be-
cause the current body size exceeds the limits for
a transseptal approach. Additionally, the transvalvular entry
into the atrium facilitates the cannulation of the pulmonary
veins. Nevertheless, these limitations might be overcome
by future designs. Currently, the idea of a stepwise implan-
tation is under construction. This includes valve deployment
after insertion of a prosthesis body into the atrium.
In our experiments we used the pig because of its very
well-suited anatomy with respect to the pulmonary veins.
In human subjects the anatomy of the atrium seems to be
much more demanding for an exclusion because of both var-
iable size and inflow of 4 pulmonary veins. Adaptation toThe Journal of Thoracic and Caeach patient would require an individual sizing process, in-
cluding imaging and measurement of the native atrium and
pulmonary ostia, followed by selection of an appropriately
sized or even a personalized fabrication of the hollow
body, a process modern production technology is able to
provide (rapid prototyping).LIMITATIONS
Because our treatment of valvular disease favors a com-
pletely new approach to the subject, our study was planned
as a proof of concept. Therefore all midterm and long-term
results will have to be tested in further experiments. These
will first of all have to dispel concerns about long-term sta-
bility and chronic cardiac complications.CONCLUSION
We demonstrated the principal feasibility of a new ap-
proach to additionally place a heart valve in the AV position
in a complex collapsible and self-expanding hollow body.
The new type of prosthesis led to an exclusion of a complete
heart chamber. Further work based on this concept seems
promising and is on the way. Technical refinements and
long-term experiments are needed for terminal judging of
this approach.References
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